Vitrolife AB (Publ): Interim Report January-June 2015: Good Growth and Strengthened Income

Regulatory News:

Vitrolife (STO:VITR)

Second quarter:

· Sales amounted to SEK 184 (129) million, corresponding to an increase of 42 percent in SEK. Sales growth was 27 percent in local currency. The acquisition of Vitrolife A/S (formerly Unisense FertiliTech A/S) contributed SEK 32 million to sales. Adjusted for this, sales growth amounted to 5 percent in local currency.

· Operating income before depreciation and amortization (EBITDA) amounted to SEK 62 (38) million, corresponding to a margin of 34 (29) percent. Fluctuations in exchange rates had a positive effect of SEK 9 million on EBITDA.

· Net income amounted to SEK 39 (23) million, which gave earnings per share of SEK 1.77 (1.16).

First half year:

· Sales amounted to SEK 347 (249) million, corresponding to an increase of 39 percent in SEK. Sales growth was 23 percent in local currency. The acquisition of Vitrolife A/S (formerly Unisense FertiliTech A/S) contributed SEK 54 million to sales. Adjusted for this, sales growth amounted to 4 percent in local currency.

· Operating income before depreciation and amortization (EBITDA) amounted to SEK 116 (74) million, corresponding to a margin of 33 (30) percent. Fluctuations in exchange rates had a positive effect of SEK 20 million on EBITDA.

· Net income amounted to SEK 74 (46) million, which gave earnings per share of SEK 3.38 (2.28).

Gothenburg, July 14, 2015

VITROLIFE AB (publ)

Thomas Axelsson, CEO

Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on July 14, 2015 at 08:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

Vitrolife is an international medical device Group. Vitrolife Fertility product area develops, produces and markets medical devices for assisted reproduction. Work is also carried out to enable the use and handling of stem cells for therapeutic purposes

Vitrolife has approximately 330 employees and the company's products are sold in almost 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in USA, Australia, France, Italy, United Kingdom, China, Japan, Hungary and Denmark. The Vitrolife share is listed on NASDAQ OMX Stockholm, Mid Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail: info@vitrolife.com. Website: www.vitrolife.com/

This information was brought to you by Cision http://news.cision.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20150713006446/en/